{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:27:37Z","timestamp":1787498857823,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T00:00:00Z","timestamp":1557532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23\u2010A\u201016"],"award-info":[{"award-number":["23\u2010A\u201016"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although dose reduction of S\u20101 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5\u2010fluorouracil, 5\u2010chloro\u20102,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S\u20101 in patients with renal impairment. We classified patients receiving S\u20101 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (\n                    <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>\n                    ) equation. The daily S\u20101 dose was adjusted based on the patient's\n                    <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>\n                    and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (\n                    <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>\n                    \u00a0\u2265\u00a080\u00a0\n                    <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                    \/min\/1.73\u00a0m\n                    <jats:sup>2<\/jats:sup>\n                    ), 10 patients in cohort 2 (\n                    <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>\n                    \u00a0=\u00a050\u201079\u00a0\n                    <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                    \/min\/1.73\u00a0m\n                    <jats:sup>2<\/jats:sup>\n                    ), 10 patients in cohort 3 (\n                    <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>\n                    \u00a0=\u00a030\u201049\u00a0\n                    <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                    \/min\/1.73\u00a0m\n                    <jats:sup>2<\/jats:sup>\n                    ), and 3 patients in cohort 4 (\n                    <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>\n                    \u00a0&lt;\u00a030\u00a0\n                    <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                    \/min\/1.73\u00a0m\n                    <jats:sup>2<\/jats:sup>\n                    ). Those in cohorts 3 and 4 treated with an adjusted dose of S\u20101 showed a similar area under the curve for 5\u2010fluorouracil (941.9\u00a0\u00b1\u00a0275.6 and 1043.5\u00a0\u00b1\u00a0224.8\u00a0ng\/\n                    <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                    , respectively) compared with cohort 2 (1034.9\u00a0\u00b1\u00a0414.3\u00a0ng\/\n                    <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                    ). Notably, while there was a statistically significant difference between cohort 1 (689.6\u00a0\u00b1\u00a0208.8\u00a0ng\/\n                    <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                    ) and 2 (\n                    <jats:italic>P\u00a0<\/jats:italic>\n                    =\n                    <jats:italic>\u00a0<\/jats:italic>\n                    0.0474) treated with an equal dose of S\u20101, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S\u20101 in patients with impaired renal function using\n                    <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>\n                    is appropriate and safe.\n                  <\/jats:p>","DOI":"10.1111\/cas.14025","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T22:58:35Z","timestamp":1555369115000},"page":"1987-1994","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic study of the oral fluorouracil antitumor agent S\u20101 in patients with impaired renal function"],"prefix":"10.1111","volume":"110","author":[{"given":"Keiko","family":"Goto","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology National Cancer Center Hospital Tokyo Japan"},{"name":"Department of Medical Oncology and Hematology Kobe University Graduate School of Medicine Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-0800","authenticated-orcid":false,"given":"Yutaka","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology National Cancer Center Hospital Tokyo Japan"},{"name":"Department of Experimental Therapeutics National Cancer Center Hospital Shimane Tokyo"},{"name":"Division of Respiratory Medicine Mitsui Memorial Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Isobe","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Respiratory Medicine Department of Internal Medicine Faculty of Medicine Shimane University Shimane Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Chayahara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Kobe University Graduate School of Medicine Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Kobe University Graduate School of Medicine Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Mukohara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Kobe University Graduate School of Medicine Kobe Japan"},{"name":"Department of Breast and Medical Oncology National Cancer Center Hospital East Kashiwa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Tsubata","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Respiratory Medicine Department of Internal Medicine Faculty of Medicine Shimane University Shimane Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Hotta","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Respiratory Medicine Department of Internal Medicine Faculty of Medicine Shimane University Shimane Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-9927","authenticated-orcid":false,"given":"Kenji","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Breast and Medical Oncology National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology National Cancer Center Hospital Tokyo Japan"},{"name":"Department of Experimental Therapeutics National Cancer Center Hospital Shimane Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8630-9145","authenticated-orcid":false,"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Kobe University Graduate School of Medicine Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,5,11]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"4004","article-title":"Inhibition by oxonic acid of gastrointestinal toxicity of 5\u2010fluorouracil without loss of its antitumor activity in rats","volume":"53","author":"Shirasaka T","year":"1993","journal-title":"Can Res"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199607000-00010"},{"key":"e_1_2_7_4_1","first-page":"2602","article-title":"Antitumor activity of 1\u00a0M tegafur\u20100.4\u00a0M 5\u2010chloro\u20102,4\u2010dihydroxypyridine\u20101\u00a0M potassium oxonate (S\u20101) against human colon carcinoma orthotopically implanted into nude rats","volume":"56","author":"Shirasaka T","year":"1996","journal-title":"Can Res"},{"key":"e_1_2_7_5_1","first-page":"2000","article-title":"Pharmacokinetic study of S\u20101, a novel oral fluorouracil antitumor drug","volume":"5","author":"Hirata K","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0457-z"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-004-0306-3"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.04.010"},{"key":"e_1_2_7_10_1","first-page":"2131","article-title":"Chromium\u201051\u2010EDTA clearance in adults with a single\u2010plasma sample","volume":"39","author":"Martensson J","year":"1998","journal-title":"J Nucl Med"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.322"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V62257"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00004"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-2966-1"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(96)00429-X"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn718"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00773.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000337232"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-015-0536-6"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1985.205"},{"key":"e_1_2_7_23_1","unstructured":"Diseases NIoDaDaK.Creatinine Standardization Recommendations 2015.https:\/\/www.niddk.nih.gov\/health-information\/health-communication-programs\/nkdep\/lab-evaluation\/gfr\/creatinine-standardization\/recommendations\/Pages\/recommendations.aspx. Cited May 14 2017."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hys235"}],"updated-by":[{"DOI":"10.1111\/cas.14402","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T00:00:00Z","timestamp":1586822400000}}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.14025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.14025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.14025","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.14025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T15:13:59Z","timestamp":1694358839000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.14025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/cas.14025"],"URL":"https:\/\/doi.org\/10.1111\/cas.14025","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,11]]},"assertion":[{"value":"2018-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}